Bioventus Inc. Class A Common Stock vs. Stryker Corporation
Bioventus Inc. Class A Common Stock (BVS) comes out ahead, leading on 5 of 9 compared factors.
Size & Scale
| BVS | SYK | |
|---|---|---|
| Market Cap | $1.20 billion | $130.11 billion |
| Revenue (TTM) | $581.85 million | $25.84 billion |
| Net Income (TTM) | $61.48 million | $3.73 billion |
SYK leads on 3 of 3 size & scale factors.
Valuation
| BVS | SYK | |
|---|---|---|
| P/E Ratio | 18.52 | 35.15 |
| Price / Book | 4.32 | 5.42 |
| Price / Sales | 2.06 | 5.04 |
BVS leads on 3 of 3 valuation factors.
Profitability
| BVS | SYK | |
|---|---|---|
| Net Margin | 10.57% | 14.43% |
| Return on Equity | 22.16% | 15.55% |
BVS and SYK split the profitability factors evenly.
Dividend
| BVS | SYK | |
|---|---|---|
| Dividend Yield | — | 1.04% |
| Payout Ratio | — | 36.48 |
BVS and SYK split the dividend factors evenly.
Risk & Sentiment
| BVS | SYK | |
|---|---|---|
| Short Interest | 0.78% | 1.53% |
BVS leads on 1 of 1 risk & sentiment factors.
Dig deeper: BVS overview, BVS financials, SYK overview, SYK financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.